Portfolio Companies
Fina Biosolutions LLC
Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. FinaBio has since grown to offer a variety of bioconjugation and protein services. The company is located in the heart of Maryland’s biotechnology corridor.
20/20 Optimeyes Technologies
OptimEyes' MNP (Mucoadhesive Nanoparticles) platform delivers small-molecule drugs directly to mucosal surfaces via a mucoadhesive polymer system that enables sustained, localized drug release. This approach improves bioavailability, compliance and safety, and supports topical delivery for multiple indications. The technology is applicable to all mucosal surfaces, across ophthalmology, respiratory, urogenital, women’s health, oncology and CNS pathologies.
Enable Biotech
Enable Biotech Ltd, founded in 2023 in Zug, Switzerland, is offering innovative custom fee for service activities in the development and clinical manufacturing of Cell & Gene Therapies (ATMPs) and Exosome Therapies. As part of its service offering, Enable Biotech offers clinical GMP mancufacturing activities for Cell Therapies and Exosome Therapies and as of Summer 2024 clinical GMP manufacturing activities for Gene Therapies (awaiting accreditation by SwissMedic).
FABP Biotech Animal Health
FABP Biotech is a spin-off of the Oswaldo Cruz Foundation (Fiocruz) created to develop anti-helminth vaccines for animal use. The company holds the license to explore Fiocruz’s rights for the development and commercialization of vaccines and veterinary products based on Sm14, a member of the Fatty Acid Binding Proteins family.
Saccharide Therapeutics
Saccharide Therapeutics Pty Ltd (ST) is a Melbourne-based biotechnology company developing first-in-class synthetic polysaccharide-based vaccines, including clinical-ready drug candidates ST101 for potential eradication of malaria and ST208 for amplified protection against tuberculosis (TB). Demonstrated efficacy against several major bacterial pathogens and parasites in animal models is highly translatable for a range of additional human therapeutic and veterinary applications.
Mannin Research
Mannin Research Inc. is a Canadian biotech company focused on developing novel therapeutics for vascular dysfunction. Its programs centered on Angiopoietin–Tie2 biology, with an initial emphasis on ophthalmology (notably glaucoma) and broader vascular indications such as ARDS.
